Obesity (BMI Equal to or >30)NCT07844616

Investigation of Egg Intake and the Relationship Between Gut Microbiome, Metabolic, and Immune Profiles

A study testing Egg whites and Whole eggs in people with Obesity (BMI Equal to or >30) and Immune Function, run by University of Connecticut at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 to 50 yearsHealthy volunteers can take part
Conditions the study is for: Obesity (BMI Equal to or >30), Immune Function, HDL
What is being tested?: Egg whites and Whole eggs
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 78 participants
Where: 1 siteUnited States
Study dates: 5 Oct 2026to 31 Dec 2027
Phase: Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 50 years
All sexes
Healthy volunteers accepted
Adult

Who may be able to join

18-50 years old (at time of screening)
Premenopausal status for women
Body mass index (BMI) 18.5 to < 25 kg/m2; or ³ 30 kg/m2 and >30% and >40% body fat for men and women, respectively
Willing to consume whole eggs and egg whites provided during the study on a daily basis, and refrain from other eggs or egg-based foods and beverages during the study
Do not fit any exclusion criteria

Who cannot join

<18 years old and ≥ 51 years old
BMI <18.5, 25-29.9, or body weight < 110 pounds
Experienced >10% weight change in the past 4 weeks
Elevated fasting glucose levels (fasting glucose higher than 126 mg/dL) and triglycerides greater than 500 mg/dL, or total cholesterol < 120 mg/dL and HDL- cholesterol < 15 mg/dL
Self-reported and/or physician-diagnosed history of severe constipation, diabetes mellitus, coronary heart disease, stroke, renal or liver disease, cancer, eating disorders, certain severe and/or relapsing/remitting autoimmune, inflammatory, intestinal or metabolic diseases, chronic infections, scleroderma, blood clotting disorders, intravenous drug use, or current pregnancy or lactation, postmenopausal
Allergy to eggs

Show all 9Show fewer

Implanted medical device (e.g., pacemaker) or other health condition that would prevent measurement of body composition by bioelectrical impedence
Currently taking lipid-lowering medications (e.g., statins, fibrates), glucose-regulating medications, anti-inflammatory medications (e.g., NSAIDs, corticosteroids), or medications that primarily affect blood clotting (e.g., warfarin), long-term antibiotics or probiotics in the last 3 months or during the intervention
Active smoker

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Catherine J Andersen, PhD, RDN contact

860-486-1704

catherine.andersen@uconn.edu

United States1 site, 1 recruiting

University of Connecticut
Storrs, Connecticut, 06269
Catherine J. Andersen, PhD, RDN, 860-486-1704, catherine.andersen@uconn.edu
Recruiting

Other trials in United States

About this study

The purpose of this intervention study is to investigate the effects of daily egg intake on markers of gut health, high-density lipoprotein (HDL), metabolic, and immune cell profiles in adults with body mass indexes (BMI) in normal and obesity ranges. This study further aims to determine whether egg effects are associated with baseline gut microbiome profiles, and whether egg effects are different between males and females and by BMI status. The study will address the following objectives:

Objective 1: Evaluate the effects of daily egg white vs. whole egg intake on gut health, microbiome, and metabolome profiles.

Objective 2: Evaluate the effects of daily egg white vs. whole egg intake on HDL composition and function.

Objective 3: Evaluate the effects of daily egg white vs. whole egg intake on immune profiles and function in culture (ex vivo).

Participants will be asked to consume egg whites and whole eggs on a daily basis for 4-weeks each, and avoid eating eggs for a total of 8 weeks at different points in the study. Participants will be asked to complete surveys about dietary intake and physical activity, as well as provide blood and stool samples throughout the course of the study.

Conditions: Obesity (BMI Equal to or >30), Immune Function, HDL, Gut Microbiome, Healthy Adult Participants
Being tested: Egg whites, Whole eggs
Keywords: Eggs, HDL, Obesity, Diet intervention, Nutrition, Gut microbioome, Immune function
Medical subject headings: Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Egg whitesOther
3 large egg equivalent of liquid egg whites per day for 4 weeks
Whole eggsOther
3 large whole eggs per day for 4 weeks

Study groups in NCT07844616
Study group	Role	What they receive
Egg whites	Active comparator	Not described Receives: Other: Egg whites
Whole eggs	Experimental	Not described Receives: Other: Whole eggs

What is being measured

The primary outcome is the main question the study is designed to answer.

Change in serum concentration of large HDL particles between diet periods
Measured: 4 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

5 Oct 202631 Dec 2027

First posted28 Sep 2026
Study start5 Oct 2026
Primary completion31 Dec 2027 (estimated)
Study completion31 Dec 2027 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Obesity (BMI Equal to or >30)Studies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Basic science
Allocation: Randomised
Intervention model: Crossover
Masking: None (open label)
Enrolment: 78 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07844616
Sponsor's protocol ID: B2025-0404/25-08-494-910
Other IDs: 2025-67017-45105, 2025
Status last verified: Oct 2026
First submitted: 22 Sep 2026
Last updated: 22 Oct 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Undecided

Interested in taking part?

Catherine J Andersen, PhD, RDN

860-486-1704

catherine.andersen@uconn.edu

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Not yet recruitingPhase 2
A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN OBESE ADULTS.
Obesity / Overweight, Obesity (BMI Equal to or >30)
Not yet recruiting
Time-Restricted Eating and Personalized Energy-Restricted Diet in Obese Postmenopausal Women
Obesity (BMI Equal to or >30), Postmenopausal Symptoms
Not yet recruitingPhase 1
Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
Alcohol Use Disorder (AUD), Obesity (BMI Equal to or >30)

All Obesity (BMI Equal to or >30) trials